Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin

Antonio Requena, María Cruz, Francisco J Ruiz, Juan A García-Velasco, Antonio Requena, María Cruz, Francisco J Ruiz, Juan A García-Velasco

Abstract

Background: Luteinizing hormone (LH) activity in human menopausal gonadotropin (hMG) preparations is derived from human chorionic gonadotropin (hCG) rather than LH. Therefore, we aimed to determine whether there are similarities in the endocrine and follicular profiles of serum and follicular fluid from controlled ovarian stimulation with the recombinant gonadotropins follicle-stimulating hormone plus luteinizing hormone (rFSH + rLH) or highly purified human menopausal gonadotropin (HP-hMG).

Methods: We performed a prospective observational study with 50 oocyte donors that received either a combination of recombinant gonadotropins (rFSH + rLH) or a mixture of urinary gonadotropins (HP-hMG) plus purified urinary FSH (uFSH). Results were analyzed using Student's t-test to compare continuous variables and the chi-squared test to compare proportions. P-values < 0.05 were considered statistically significant.

Results: Although more oocytes were retrieved after treatment with recombinant than urinary gonadotropins (16.5 vs. 11.8; P = 0.049), a higher proportion of metaphase II ova (71.2% vs. 80.6%; P = 0.003) were obtained using urinary gonadotropins. On day 6 and on the day of triggering, serum steroid hormone levels were slightly but not significantly elevated in the recombinant group compared with the urinary group. In follicular fluid, no statistical differences were observed for intra-follicular levels of steroid hormones between the two protocols; ongoing pregnancy rates were similar (46.1% vs. 46.1%).

Conclusions: Our data suggest that endocrinological and follicular profiles do not differ between rFSH + rLH and HP-hMG stimulation.

Figures

Figure 1
Figure 1
Graphical illustration of the distribution of patients.
Figure 2
Figure 2
Follicular development on the day of hCG administration.

References

    1. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21:3217–3227. doi: 10.1093/humrep/del284.
    1. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97:561–571. doi: 10.1016/j.fertnstert.2011.12.016.
    1. Van Wely M, Westergaard LG, Bossuyt PMM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles (Review), Cochrane Database of Systematic reviews. The Cochrane Collaboration, Published by John Wiley and sons, Ltd; 2003.
    1. Wolfenson C, Groisman J, Couto AS, Hedenfalk M, Cortvrindt RG, Smitz JE, Jespersen S. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005;10:442–454. doi: 10.1016/S1472-6483(10)60819-X.
    1. Smitz J, Andersen AN, Devroey P, Arce JC. MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22:676–687.
    1. Koulianos G. Gonadotropins in the treatment of infertility. US Obstetrics & Gynecology. 2009;4:29–36.
    1. Platteau P, Nyboe Andersen A, Loft A, Smitz J, Danglas P, Devroey P. Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online. 2008;17:190–198. doi: 10.1016/S1472-6483(10)60194-0.
    1. Orme B. Getting started with conjoint analysis: strategies for product design and pricing research. Madison, WI (USA): Research Publishers, LLC; 2006.
    1. Garrido N, Zuzuarregui JL, Meseguer M, Simon C, Remohi J, Pellicer A. Sperm and oocyte donor selection and management: experience of a 10 year follow-up of more than 2100 candidates. Hum Reprod. 2002;17:3142–3148. doi: 10.1093/humrep/17.12.3142.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
    1. Alikani M, Calderon G, Tomkin G, Garrisi J, Kokot M, Cohen J. Cleavage anomalies in early human embryos and survival after prolonged culture in-vitro. Hum Reprod. 2000;15:2634–2643. doi: 10.1093/humrep/15.12.2634.
    1. Remohi J, Gallardo E, Guanes PP, Simon C, Pellicer A. Donor-recipient synchronization and the use of gonadotrophin-releasing hormone agonists to avoid the premature luteinizing hormone surge in oocyte donation. Hum Reprod. 1995;10(Suppl 2):84–90. doi: 10.1093/humrep/10.suppl_2.84.
    1. Yding AC. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online. 2002;5:232–239. doi: 10.1016/S1472-6483(10)61826-3.
    1. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16:81–88. doi: 10.1016/S1472-6483(10)60559-7.
    1. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23:310–315.
    1. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, Pignatti E, Simoni M. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS One. 2012;7:e46682. doi: 10.1371/journal.pone.0046682.
    1. Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC. MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod. 2007;22:2404–2413. doi: 10.1093/humrep/dem221.
    1. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Menopur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010;94:2467–2469. doi: 10.1016/j.fertnstert.2010.04.035.
    1. Eldar-Geva T, Margalioth EJ, Brooks B, Algur N, Zylber-Haran E, Diamant YZ. The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles. Hum Reprod. 1998;13:9–14.
    1. Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod Biomed Online. 2011;23:187–195. doi: 10.1016/j.rbmo.2011.04.003.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner